Materials
All following materials were obtained as gift samples from Tehran Chemie Pharmaceutical Co., Tehran, Iran: Dexamethasone (Alborz Bulk Pharmaceutical Co., Iran), Crospovidone (Kollidon CL-SF, BASF, Germany), Mannitol (Pearlitol SD200, Roquette America, USA), Prosolv silicified microcrystalline cellulose (Prosolv SMCC90 JRS,USA), Lactose (Pharmatose DC14 DMV international, Holand), Magnesium stearate (St-Mg), Sodium chloride, Citric acid, flavours (Kerpen, Germany), Saccharin sodium and Aspartame. All other chemicals and solvents used were of analytical grade.
Methods
Experimental Design
Design of experiment with the minimum number of experiments in preparing formulations with different variables comes to save time and costs. Methods used in experimental design include: mixture, factorial, combined, and response surface (
21). In this study Box-Behnken response surface methodology as a model of Design Expert Software (Version 7, Stat- Ease Inc., Minneapolis, MN) for optimizing ODTs of DEX and assessment of data is used. After basic studies to choose effective factors and determining levels of each factor, the independent factors were concentrations of Kollidon CL-SF (X
1), Pearlitol SD200 (X
2), and Prosolv SMCC (X
3), each were studied at three levels.
Table 1 shows the domain of each factor. The effects of these three factors were assessed for four responses, including: percentage of drug released after 5 min (Y
1), disintegrating time (Y
2), hardness (Y
3), and friability (Y
4) – used as dependent variables. The highest and the lowest level of each factor are coded as 1 and -1 respectively and 0 is the mean value. The central point is repeated three times to estimate experiments errors. Each of dependent variables can be shown with one polynomial equation:
(1)
Y = measured response, B
0 = intercept, B
1-B
33 = regression coefficients for the factors and X
1, X
2 and X
3 = independent factors, X
iX
j = the interaction terms, and X
2i (i = 1, 2 or 3) are the quadratic terms. Value of factors reflects the effect of dependent variables. At each stage, the multiple correlation coefficient (R
2) was calculated to show the model accuracy. Positive (+) and Negative (–) coefficients show the synergistic effect and the antagonistic effect, respectively. Statistical significance test of each effect is studied with ANOVA in which, if the
P-value is <0.05, the effect is significant. Finally, in order to illustrate the relationship between the different experimental variables and the responses, contour plots and response surface 3D plots were generated (
21,
23-
29).
| Levels
|
|---|
| Low (−1) (%) | Middle (0) (%) | High (1) (%) |
|---|
| Independent variable, factorX 1: Kollidon CL-SF concentration | 5 | 10 | 15 |
| X 2: Pearlitol SD200 concentration | 25 | 35 | 45 |
| X 3: Prosolv SMCC concentration | 2.5 | 5 | 7.5 |
| Dependent variable, response | Constraints |
| Y 1 = drug released after 5 min (%) | Maximize |
| Y 2 = disintegration time (s) | Minimize |
| Y 3 = hardness (kg) | Maximize |
| Y 4 = friability (kg) | Minimize |
Formulation of Dexamethasone orally disintegrating tablets (ODTs)
Prior to formulation preparation, physicochemical properties of DEX like organoleptic properties, bulk density, tapped density, flow, and compressibility have been studied. Bulk density (D
b) was measured by the USP method I and tapped density (D
t) was determined by USP method II using a tapped density tester (Aymes, Turkey). Carr’s or Compressibility Index and Hausner Ratio of DEX and powder mix which are used to compare the flow and compressibility of the powder before and after blending are measured with the following equations (
10,
30):
(2)
(3)
In order to prepare ODTs containing 2% (4 mg) DEX and 1% magnesium stearate with a total weight of 200 mg, direct compression method was utilized. The other components vary according to the Box-Behnken design presented in
Table 2.
Ingredient (% Tablet weight)
| Precompression parameters
|
|---|
| RUN NO | Dexamethasone(API) | CrospovidoneKollidon CL-SF | PearlitolSD200 | ProsolvSMCC | Mg Stearate | LactoseDCL14 | Carr’s index (%) | Flow |
|---|
| 12345678910111213 | 2222222222222 | 1015155551010105151015 | 25352535453545453525452535 | 7.57.557.552.57.52.55552.52.5 | 1111111111111 | 54.539.55249.54254.534.539.547623259.544.5 | 16.7716.7023.409.907.8010.108.609.0010.0610.009.6023.1421.27 | FairFairPassableExcellentExcellentGoodExcellentExcellentGoodExcellentExcellentPassablePassable |
The formulation components were weighed on a digital balance and except lubricant were sieved separately through sieve #30 mesh. After geometrical blending of components, they were put in a polyethylene bag and were mixed under proper circular movements for 10 min. Magnesium stearate after passing through sieve #60 mesh was blended with other ingredients for 1 min. The final blend was put into the compression device (rotary tableting machine, Manesty, England) and compressed into tablets using 8 mm flat die and punches. In every batch, 40 tablets were produced. After final blending and before tablet compression, flow of each formulation was evaluated according to the mentioned method, because flow of powder is important in tablet uniformity.
Characterization of ODTs
The physicochemical properties of different Dexamethasone ODT formulations such as appearance, diameter and thickness, uniformity of weight, and the influence of different excipients as independent variables on % drug released after 1 min, disintegration time, hardness and friability as dependent responses were investigated (
31-
34).
Assessment of diameter, thickness and weight variation
Twenty tablets of each formulation were randomly chosen and their diameter and thickness were measured by vernier callipers. For weight variation test, 20 tablets were randomly selected from each run and separately weighed by analytical scale and the average and standard deviation were calculated. Weight variation is a proper method to measure drug content uniformity (
35). Considering the weight of each is 200 mg, maximum standard deviation is, according to USP, 7.5%. Not more than two tablets should exceed this domain; nor, none of the tablets should exceed twice the allowed perimeter (
36).
Assessment of Experimental design variables
In-vitro dissolution studies
ODTs Dissolution study is similar to regular tablets; except for apparatus – USP II (paddle), which is a more common and proper device for ODTs. The In-vitro drug release was studied using USP Apparatus Type II (Paddle) (Electrolab, TDT-08L India), in 500 mL 0.1N hydrochloric acid as medium at 100 rpm and at 37 ± 0.5 °C. At time intervals of 1, 5, 10, 20, 45 min, 5 mL of the dissolution medium was taken and to keep the balance of the sink condition, the same amount of volume from the fresh medium of dissolution – already reached to the desired temperature – was replaced. Thereafter, the samples were filtered and assayed using the (Shimadzu UV/visible 1700 spectrophotometer Japan) at 243 nm wavelength.
Disintegration time
Disintegration time was carried out using disintegration test apparatus (Electrolab, India). Nine-hundred mL of distilled water at 37 ± 2 °C was used as the disintegration medium. Six tablets per batch were chosen randomly and placed in the disintegration apparatus. Disintegration time was considered when the tablets dispersed and all the tablet fragments passed through the mesh completely. This experiment was repeated in triplicates, and then the average and standard deviation were recorded.
Hardness
Hardness of tablets was measured using a tablet hardness tester (Type TBH220TD, Erweka, Germany). A tablet was put into the device, and the force needed to break the tablet was recorded. Twenty tablets were evaluated in each run, and the average hardness and the standard deviation were calculated.
Friability test
This test was operated with Friability test apparatus (Electrolab, India). Twenty tablets in each run chosen randomly and already weighed were placed in the device and rotated with the speed of 25 rpm. After 4 min of rotating in the device, the tablets were dedusted and weighed again. The percentage friability of tablets is measured using the following equation:
(4)
Complementary tests
Taste evaluation
After analysing the data of experimental design, and choosing optimized formulation, complementary tests were done on the optimized formulation. Since DEX has an unpleasant taste, and due to ODT disintegration in the mouth, and to improve patient compliance, the next stage – after optimizing and choosing the optimized formulation – is masking of the unpleasant taste of the tablet. In spite of the presence of excipients like Kollidon CL-SF, and the smooth cream-like mouth feel associated with its use, and also Pearlitol 200 SD due to freshness and sweetness it creates in the mouth, adding flavours, citric acid, sodium citrate and sodium chloride in proper dosages to improve the taste of the formulation seems necessary (
37,
38). Table 3 shows the type and percentage of the materials in the taste evaluation test. In order to conduct the experiment, 10 volunteers were selected from healthy people between 20-40 years old from both sexes (5 males and 5 females), and due to moral principles, they were informed about the nature of the drug and the procedure, before conducting the experiment; also, they were asked to – with patient satisfaction – wash their mouths and put the tablet on their tongue, and refuse from swallowing the tablet during the test, and after the disintegration and testing the taste with the help of visual analogue scale, rinsed their mouths with water. According to the following scale, taste scale was rated in 6 levels (0 = like extremely, 2 = like moderately, 4 = like slightly, 6 = dislike slightly, 8 = dislike moderately and 10 = dislike extremely). Volunteers scored 0 for the best taste and 10 for the worst. Therefore, F formulation series was studied for the compliance of administrator (
1,
39 and
40).
| Ingredients | Quantity (mg/Tab)
|
|---|
Flavour selection
| Sweetener selection
|
|---|
| F1 | F2 | F3 | F4 | F5 |
|---|
| Dexamethasone (2%) | 4 | 4 | 4 | 4 | 4 |
| Kollidon CL_SF (15%) | 30 | 30 | 30 | 30 | 30 |
| Pearlitol SD200 (39.66%) | 79.32 | 79.32 | 79.32 | 79.32 | 79.32 |
| Prosolv SMCC (7.5%) | 15 | 15 | 15 | 15 | 15 |
| Pharmatose DCL14 (26.84%) | 53.68 | 53.68 | 53.68 | 53.68 | 53.68 |
| Magnesium stearate (1%) | 2 | 2 | 2 | 2 | 2 |
| Citric acid (3%) | 6 | 6 | 6 | 6 | 6 |
| Sodium chloride (2%) | 4 | 4 | 4 | 4 | 4 |
| Orange flavour (1%) | 2 | | | | |
| Lemon flavour (1%) | | 2 | | | 2 |
| Peppermint flavour (1%) | | | 2 | | |
| Grape flavour (1%) | | | | 2 | |
| Saccharin (2%) | 4 | 4 | 4 | 4 | |
| Aspartame (2%) | | | | | 4 |
| Total (mg) | 200 | 200 | 200 | 200 | 200 |
Water absorption ratio
The tablet which had already been weighed was placed on the surface of a paper folded twice into a petri dish containing 6 mL distilled water. When the tablet absorbed the water completely, was weighed again, and the absorption ratio was measured according to the equation 5 (
41).
(5)
When Wa and Wb were tablet weights before and after water absorption
Determination of drug content
To determine drug content in the optimized formulation, 10 dexamethasone ODTs were selected from the optimized formulation and crushed into powder in a mortar. An equivalent of one tablet weight was transferred into a 50-mL volumetric flask, then 25 mL solution (methanol: water 1: 2 v/v) was added. The flask was shaken and sonicated for 15 min, and then the solution was diluted to required volume with the same fluid, and after filtering through filter paper the absorption ratio was read – using spectrophotometer at pre-determined λmax of 241 nm. Finally, drug content in the optimized formula is measured.